Surprisingly, resistomycin treatment dose-dependently upregulated the expression of phosphor-p38 and phosphor-MAPKAPK-2 but expression of p38 remained unchanged (Figure 4A,B), suggesting the possibility that p38 MAPK may be associated with the anti-cancer activities of resistomycin. Here, MAPKAPK2 is linked to cancer.